Project Objectives: 

• Develop and implement regulatory strategies aligned to clinical trial and device submission requirements.
• Compile and review regulatory dossiers in accordance with country-specific requirements (e.g., CDSCO, FDA, EMA, PMDA etc).
• Ensure submission packages were complete, accurate, and aligned with applicable standards (ICH, GCP, ISO 14155 etc).
• Facilitate smooth and timely communication with health authorities.
• Support query responses, amendments, and lifecycle submissions.

Techsol Approach:   

Strategic Planning: 

• Collaborated with client regulatory teams to understand product profiles, submission timelines, and target markets.
• Identified applicable regulatory frameworks including 21 CFR Part 312 (USA), NDCT Rules 2019 (India), MDR 2017, EU MDR, EU IVDR & country-specific mandates.
• Developed customized regulatory roadmaps for Clinical Trial Applications, Import License, Medical Device Clinical Investigations and Product Registrations.

• Conducted comprehensive gap assessments against authority requirements.
• Identified missing technical, clinical, and quality data.
• Created region-specific checklists covering required forms, labeling formats, and declarations.
• Performed internal quality review and ensure documents meet regional formatting and technical standards.

Dossier Preparation and Compilation:

Techsol regulatory team prepared complete and compliant submission packages aligned with the specific requirements of global health authorities such as the US FDA, EMA, CDSCO.

• For medical devices, we ensured that all technical documentation was compiled as per relevant regulatory authorities such as MDR 2017, EU MDR Annex II and III, including device descriptions, design and manufacturing information, risk management files, clinical evaluation reports, and post-market surveillance documentation.
• For biopharma products, we prepared CTD-format dossiers compliant with ICH M4 guidelines, covering modules on quality, non-clinical, and clinical data. Used validated publishing tools and adherence to regional guidance (e.g., Module 1 requirements) support seamless compilation and submission.

Submission Management:

• We facilitated electronic submissions via regional portals such as the US FDA ESG gateway, EMA’s Common European Submission Portal (CESP), India’s SUGAM and NSWS systems, and the EU Clinical Trials Information System (CTIS).
• We have successfully submitted all regulatory dossiers within the stipulated timelines and effectively managed responses to deficiency letters, FDA Information Requests (IRs), Notified Body questions during EU conformity assessments, and CDSCO queries related to clinical trial applications, product imports, and medical device clinical investigations.
• Handled eCTD publishing, XML backbone creation, and document granularity.

                                                                                  Process Flow

 

Challenges:   

• To ensure full adherence to Medical Device regulatory standards, which includes MDR 2017, labeling,  risk assessment, and robust Post-Market Surveillance (PMS) strategy.
• To prepare a quality, submission-ready import license/ Product Registration dossier before submission to minimize the possibility of CDSCO queries.
• To obtain the approval of Import License / Product Registration within the stipulated timelines of the original application being submitted to Regulatory Authority

Techsol Approach :  

Our client’s medical devices were intended to be imported and distributed commercially in India from Germany. Techsol established a systematic approach for regulatory Strategy that was tailored to the project’s commercial timelines and CDSCO guidelines.

Phase 1: Project Initiation and Planning

• Kick-off Meeting: Upon contract signoff Techsol Project Manager will conduct a detailed kick-off meeting with the sponsor to align on scope, timelines, expectations, and responsibilities 
• Regulatory Strategy: Techsol Regulatory team will review the medical device details confirming its risk classification as per Indian MDR 2017 rules and develop the regulatory strategy for the Import License/ Product registration approval process in India. 
• Gap Assessment: Techsol Regulatory Team will provide the gap analysis checklist to the Sponsor, upon receiving documents from the sponsor, Techsol Regulatory team will review the source documents and confirm the classification of the device as per the Indian MDR 2017. If any deficiencies/gaps are identified same will be communicated to the sponsor 

Phase 2: Dossier Compilation and Submission

• Covering Letter
• Power of Attorney (POA)
• Copy of Whole Sale license / Manufacturing license
• Free Sale Certificate (FSC)
• Overseas Manufacturing Site Registration Certificate
• Quality Certificates (ISO 13485)
• CE Certificates (Product/Design/Type)
• Declaration of Conformity
• Site Master File (SMF) / Plant Master File (PMF)
• Device Master File (DMF)
• Instruction for use (IFU)

• Authentication of Regulatory Documents: Notarized, apostilled, or embassy-authenticated copies of documents (e.g., Power of Attorney, Free Sale Certificate, CE Certificate, Quality Certificate, and Manufacturing Site Certificate) were required but initially submitted without proper attestation, leading to delay in regulatory approval.

They approached Techsol Life Sciences to manage the full lifecycle of Structured Product Labeling (SPL) for its product line, covering new product entries (SPL Creation), SPL Updation (safety updates), and Delisting (product discontinuation).

Project Objectives: 

To provide end-to-end management of Structured Product Labeling (SPL) focusing on SPL Creation, Update, and Delisting, ensuring full regulatory compliance with U.S. FDA labelling requirements and HL7 standards.

• SPL Creation: To Create a structured product labeling (SPL) in XML format for newly approved drug, ensuring it meets the FDA’s labeling and submission standards.
• SPL Update: To update the existing drug SPL with latest safety information and labels to comply with FDA standards.
• SPL Delisting: To ensure the efficient removal of a drug listing from the FDA’s Structured Product Labeling (SPL) database.

Techsol Approach:   

Project Initiation: Upon contract signoff Techsol Project Manager will provide the brief overview about the project scope, timelines, expectations, and responsibilities.

Gap Analysis: Techsol Regulatory team will perform a detailed gap analysis to identify missing/ required information in the following categories:  

• Header Elements: Drug name and details, Version details, Labeller information, Registrant details, Establishment and business operations.
• Data Elements: Drug names, dosage form, Application details, Marketing date, Characteristics, and Packaging Information.
• Contents of Labeling: Information for all required sections, Revised date, IFU (if applicable) and Labels.

• SPL Creation: The SPL creation process begins with extracting relevant information from the client’s source Prescribing Information Leaflet (PIL). This data is carefully incorporated into designated sections of the SPL, including Header information, Data Elements, and contents of labeling. Depending on the dosage form, additional sections such as Labels, Instructions for Use (IFU), and Medication Guides are completed with appropriate content. 
• SPL Update: Updating the SPL content in XML format, including Document IDs, Section IDs, Version Number, Revised date, New labels with existing labels and other content of labeling sections with outdated or new information mainly Warnings and Precautions, Adverse Reactions, Drug Interactions, and Patient Counselling Information.
• SPL Delisting: The product’s marketing status was updated from “ACTIVE” to “COMPLETED.” This update is essential to signify the product’s end-of-life phase, with the marketing end date documented as required by the FDA, typically using the expiration date of the last produced lot. 

Validation and Error resolution: Once all necessary data is integrated, the SPL is validated to verify XML compliance. Any XML or structural errors identified during validation are corrected using SPL validation guide to ensure full compliance with labelling requirements.

Final QC: Designated personnel will perform the QC review to ensure all content meets FDA requirements, is free of validation errors, and accurately reflects updated safety information.

                                                                                 QC Process Flow

 

Our client, a leading biopharmaceutical company with a legacy spanning over seven decades, is renowned for its commitment to producing affordable, high-quality vaccines and has contributed significantly to global immunization programs, particularly in developing countries. As part of its expanding business portfolio and efforts to address unmet needs in pneumococcal disease prevention, the company has developed a 14-valent Pneumococcal Conjugate Vaccine (PCV14) and plans to conduct a phase IV clinical study globally. To support this initiative, the client engaged Techsol to design a clinical trial protocol that adheres to stringent international guidelines, including those of the U.S. FDA, EMA, and WHO, for multi-center trials across diverse geographic regions.

Project Aim: 

The primary aim of the project was to deliver a scientifically robust, regulatory-compliant clinical trial protocol that facilitates effective post-marketing surveillance and ensures smooth execution and timely progression through the trial phases.

Techsol Approach:   

• Client Collaboration: Interacting with client’s team and understand their scientific objectives, regulatory requirements, and anticipated challenges.  
• Regulatory Landscape Analysis: Conducting detailed review of international guidelines, including ICH E6 (R2) Good Clinical Practice (GCP), to ensure compliance. 
• Scientific Literature Review: Conducting comprehensive literature research on existing PCV formulations, the epidemiology of pneumococcal diseases, and the immunogenicity profile of conjugate vaccines. 
• Protocol Development: Our experienced medical writers collaborate with clinical researchers, biostatisticians, and medical reviewers to gather insights for drafting the protocol. 
• Stakeholder Review: Iterative reviews with the client’s scientific and regulatory teams ensure alignment with project goals. 

The client is an India-based pharmaceutical company that manufactures a wide range of drugs across various therapeutics areas. With a strong market presence, the company is deeply committed to upholding ethical standards and moral values in all its business operations. The client outsourced Techsol for drafting clinical overview (Module 2.5) for a Type 2 anti-diabetic drug, ensuring alignment with international regulatory requirements. ensuring alignment with international regulatory requirements.

Project Aim: 

The aim of the project was to develop a comprehensive, regulatory-compliant clinical overview for Type 2 anti-diabetic drug to support the client’s submission to international regulatory authorities. The clinical overview needed to be effectively demonstrate the drug’s efficacy, safety, and therapeutic benefits while aligning with the client’s commitment to ethical standards and regulatory requirements, ultimately facilitating a streamlined and successful approval process.
Techsol Approach:  

Techsol adopted structured and evidence-based apprach to understand the client’s regulatory, clinical, and ethical needs, including an in-depth review of the anti-diabetic drug’s therapeutic profile, highlighing the need for the efficacy, safety and pharmacological data. A comprehensive literature review was conducted, focusing on Type 2 diabetes management and current treatment trends. Using structured templates in line with ICH guidelines, the team drafted the clinical overview, incorporating detailed sections on pharmacology, clinical efficacy, and safety. Techsol’s internal quality assurance (QA) processes ensured each draft adhered to regulatory standards. Regular checkpoints were scheduled to review progress with the client, resulting a robast clinical overview.

A prominent pharmaceutical client serving global markets, including the US, Europe, and India, has completed a clinical trial to evaluate the efficacy and safety of an enteral nutrition product for critically ill patients. The client outsourced Techsol Lifesciences to craft a Clinical Study Report (CSR) based on the trial’s results, ensuring compliance with Regulatory Ambiguities.

Project Objective: 

The aim was to craft a fully compliant CSR that rigorously adhered to industry standards, ensuring comprehensive and precise communication of study findings, along with accurate interpretation and presentation of clinical trial data, while also addressing issues such as data limitations and scientific skepticism.
Techsol Approach:  

Techsol Lifesciences leveraged its extensive experience in medical writing and regulatory strategy to deliver a complaint CSR. The team implemented a meticulous, phased approach to ensure each CSR section aligned with global standards and meet client expectations. This process involved Techsol Medical Writing team to craft a standardized CSR template, providing a cohesive framework as necessary to enhance the clarity of data presentation. Techsol employed data visualization techniques, such as Kaplan-Meier curves, to provide a clear, visual interpretation of data. Techsol’s medical reviewer critically assessed the study design, methodology, and results to ensure that the data was robust, scientifically valid, and accurately presented. Additionally, Techsol’s QA team conducted regular compliance checks to ensure adherence to ICH E3 guidelines and Good Clinical Practice (GCP) standards. These proactive measures minimized errors, improved the overall quality of the report, and ensured that the CSR met global standards, facilitating a quickly understanding of the product’s impact on critical healthcare stakeholders.

Techsol’s strategic approach resulted in a high-quality, scientifically credible CSR that effectively addressed the challenges associated with nutraceutical trials. The CSR’s alignment with regulatory standards, transparency, and robust scientific foundation positioned the nutraceutical product favorably among both scientific and regulatory stakeholders, ultimately contributing to successful regulatory submissions and increased market acceptance.

A leading pharmaceutical company based in India, renowned for its advancements in “Specialty Nanotherapeutics,” is committed to research and development of innovative treatments, with a particular focus on central nervous system (CNS) disorders. The client approached Techsol’s expertise to develop a clinical trial protocol for a phase III CNS-targeted psychiatric product, ensuring compliance with ICH E6 R2 guidelines and NDCT 2019 regulatory standards.

Project Objective: 

The objective was to define the key components of the protocol for executing the clinical trial in India. This included calculating the Human Equivalent Dose (HED), as the API has established pre-clinical data for dose determination, and developing psychiatric scales for clinical assessments to ensure the smooth execution of the trial and achievement of its overarching goals. 

Techsol Approach:  

This involved a deep understanding of the client requirements and regulatory expectations, emphasizing the distinct aspects of CNS-focused therapeutics and specific challenges posed by psychiatric disorders. Techsol medical writing team conducted a systematic literature search, combined with a review of CTRI trial data to develop a robust trial protocol that aligned with the study objectives. Techsol’s in-house Toxicologists calculated HED, using industry-standard methodologies to ensure appropriate dosing, scientific rigor and patient safety. Recognizing the need for precise and sensitive psychiatric evaluations, Techsol’s team developed and validated specialized psychiatric scales for clinical evaluations.

• Regulatory Complexity: Ensuring compliance with both ICH E6 R2 international guidelines and India’s NDCT 2019 standards have unique and stringent requirements for CNS and psychiatric products.
• Dose Translation Accuracy: Calculating Human Equivalent Dose (HED) precisely from preclinical data, poses a vital challenge for ensuring patient safety and securing regulatory approval after animal model trials.
• Psychiatric Assessment Sensitivity: Developing psychiatric scales that can accurately capture complex CNS disorder symptoms poses a challenge for developing protocol.

Techsol innovative and crucial solutions:  

• Techsol’s medical writing and regulatory experts meticulously reviewed regulatory guidelines and ensured compliance to streamline a path to regulatory acceptance for both international and local standards. This included designing the protocol with precise eligibility criteria, study design and endpoints.
• Techsol’s toxicology expert team used an advanced dose-conversion algorithm to translate animal model data into a clinically relevant human dose. This was validated through iterative calculations and expert review to ensure dosing was scientifically sound, minimizing risk and optimizing therapeutic outcomes.
• Our medical experts selected appropriate assessment scales for CNS-related psychiatric trials, leveraging insights from Key Opinion Leaders (KOLs) and conducting an extensive literature review with accuracy and patient safety. The scales included GAD-7 and HAM-A for measuring anxiety severity, CGI-I for evaluating overall improvement, and PSQI for assessing changes in condition and sleep quality. These scales were designed to capture the CNS-related psychiatric symptoms, enhancing the precision of clinical assessments and ensuring data quality.
• Our team developed a robust and feasible study design, clearly outlining the study objectives, inclusion/exclusion criteria, treatment groups, and endpoints. By conducting comprehensive risk assessments, our team developed a detailed activity schedule along with safety protocols to be adhered to throughout the study.

Project Achievements: 

Through Techsol’s rigorous and client-centered approach, resulted in the following achievements:  

• Regulatory Approval: The protocol successfully achieved regulatory approval, demonstrating compliance with both ICH E6 R2 and NDCT 2019 requirements.
• Optimized and Safe Dosing Strategy: The precise HED calculation established a dosing framework that prioritized patient safety while ensuring therapeutic benefit.
• Accurate Psychiatric Assessment Tools: The custom-developed psychiatric scales allowed for sensitive and reliable assessments, significantly enhancing data accuracy and the potential for meaningful clinical insights.

 

Study Outcomes: 
Techsol’s expertise in developing a clinical trial protocol for a psychiatric treatment in the CNS domain. The team’s strategic and thorough approach ensured compliance with complex regulatory standards, optimized dose translation, and enabled precise psychiatric assessment. This successful collaboration positioned the client for a smooth clinical trial process and laid a strong foundation for potential future approval and market entry of a much-needed psychiatric therapeutic.
Benefits for the Client: 
The project yielded significant benefits for the client:

• Obtaining authorization from the Drug Controller General of India (DCGI) for the proposed protocol.
• Seamless implementation of the trial, free from complications or modifications, showcasing the strength of the protocol design.  
• Accomplishment of the phase III clinical trial, meeting its goals and illustrating the success of the project.